Lv63
1850 积分 2024-01-18 加入
TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
12天前
已完结
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
27天前
已完结
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
1个月前
已完结
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
2个月前
已完结
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
3个月前
已完结
Non-small-cell lung cancer
3个月前
已完结
Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma
3个月前
已完结
Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
3个月前
已完结
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
3个月前
已完结
Therapeutic options in hepatocellular carcinoma: a comprehensive review
4个月前
已完结
皖公网安备34019202002308
